What Is Emergent BioSolutions Inc. (EBS) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Emergent BioSolutions Inc. is potentially undervalued at its current price of $7.50. Based on our 13-model framework, Emergent BioSolutions Inc.'s intrinsic value is estimated at a composite fair value of $12.40 — representing +65.4% implied upside — with 9 out of 12 active models confirming this thesis. Model dispersion is worth noting: EROIC targets $26.86 (+258.1%), versus Dynamic NAV at $2.85 (-62.0%). This +320.1% range highlights the importance of multi-model analysis rather than relying on any single methodology.
What Do the Models Say About EBS?
12 of 13 models are currently active for EBS. Of these, 9 models suggest upside while 3 models suggest overvaluation. The Bayesian DCF estimates EBS's intrinsic value at $11.24, implying +49.9% upside from the current price. See which stocks rank higher →
How Does EBS Rank in Pharmaceutical Preparations?
Among 469 Pharmaceutical Preparations stocks, EBS ranks #34 by Quality of Company score. CirclFi's QOC score of 8.1/10 evaluates 32 fundamental signals. A score of 8.1 places EBS in the top tier.
See all Most Undervalued Pharmaceutical Preparations Stocks →
Emergent BioSolutions Inc.'s positioning within the Pharmaceutical Preparations segment means that R&D productivity ratio plays an outsized role in fundamental analysis. The sector's unique characteristics — including late-stage pipeline catalysts — shape both the opportunity set and risk profile.
Is EBS a Value Trap?
CirclFi's Value Trap algorithm assigns EBS a score of 12/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
12 of 13 models are active for Emergent BioSolutions Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Deep Alpha Valuation Engine, Emergent BioSolutions Inc. scores 8.1 out of 10 on our 32-signal quality assessment, a strong rating that demonstrates strong fundamentals across the majority of our quality signals. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.
The gap between the most bullish and bearish model spans +320.1% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every EBS valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across EBS's 12 active models, average confidence is 41%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad